Data from the TRACERx lung study suggest that circulating tumor DNA (ctDNA) may be a biomarker for the detection of postsurgical minimal residual disease (MRD) in patients with non–small-cell lung cancer (NSCLC), suggesting which patients are at increased risk for disease relapse and will require more aggressive adjuvant therapy.
Tumor expression of PD-L1 has consistently predicted response and survival outcomes in non–small-cell lung cancer (NSCLC), whereas the role of PD-L1 in immune cells is unclear, said Edward B. Garon, MD, Director, Thoracic Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
For the second time this month, the FDA has given an approval to Genentech’s PD-L1 inhibitor, Tecentriq. On March 18, 2019, the FDA awarded the immunotherapy agent, Tecentriq (atezolizumab; Genentech), in combination with chemotherapy (carboplatin and etoposide), approval for the first-line treatment of adults with extensive-stage small-cell lung cancer (ES-SCLC). [ Read More ]
The PD-L1 inhibitor durvalumab (Imfinzi) showed an overall survival benefit in patients with unresectable stage III non–small-cell lung cancer (NSCLC) in the phase 3 PACIFIC trial.
The Road MAP to Targeted Therapy in Squamous-Cell Carcinoma: Lung Cancer Master Protocol (SWOG S1400) Overview
Lung cancer is the leading cause of cancer-related death worldwide. More than 85% of cases of the disease are classified as non–small-cell lung cancer (NSCLC), with a predicted 5-year survival rate of 16%.1 The battle against lung cancer entered a new era with the identification of actionable genomic aberrations in [ Read More ]
Recent guidelines call for molecular testing for 2 specific actionable alterations in any patient with non–small cell lung cancer (NSCLC) with an adenocarcinoma component: EGFR mutation and ALK fusion. Testing should be performed at the time of diagnosis. A case demonstrating standard of care for the management of a patient [ Read More ]
Implementing a clinical pathway for stage IV non–small-cell lung cancer (NSCLC) led to a reduction in chemotherapy drug charges at the Cleveland Clinic, reported James Stevenson, MD. A pathway for the management of patients with nonsquamous EGFR wild-type, ALK-negative stage IV NSCLC was developed between October 2013 and July 2014. [ Read More ]
Targeted treatments have proved to be clinically successful and represent the realization of personalized medicine’s potential. In non–small cell lung cancer (NSCLC), molecularly targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib have shown dramatic responses in patients with activating mutations.1-3 EGFR [ Read More ]
FDA Approves Opdivo (Nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non–Small Cell Lung Cancer
Bristol-Myers Squibb Company announced that the Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Opdivo is the first and only PD-1 (programmed death-1) therapy to [ Read More ]
Non–small cell lung cancer is one of the major cancer types for which new immune-based cancer treatments are currently in development Lung cancer is the second most common cancer in both men and women (not counting skin cancer); in men, prostate cancer is more common, whereas in women, breast cancer [ Read More ]